Skip to main content
NVDA+0.72%AAPL-0.44%MSFT-0.85%GOOGL-1.06%AMZN+0.39%TSM+1.40%SPCX-0.40%META-0.23%AVGO+2.33%TSLA+1.03%LLY+0.45%BRK-B+1.17%MU+2.34%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.29%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+1.11%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.80%NVS+1.78%NZDMXN+0.60%USDJPY+0.58%NZDJPY+0.58%EURNZD-0.53%AUDJPY+0.52%EURUSD-0.52%AUDDKK+0.47%NZDCHF+0.47%USDCHF+0.46%CADJPY+0.46%EURAUD-0.45%GBPTRY+0.41%AUDCHF+0.41%GBPUSD-0.41%GBPNZD-0.40%EURCAD-0.37%NZDSGD+0.36%GBPAUD-0.35%EURSEK-0.34%CADCHF+0.33%GBPHKD+0.32%USDPLN+0.31%EURCNH-0.30%GBPCAD-0.29%GBPMXN-0.28%EURHKD-0.28%USDDKK+0.27%USDMXN+0.27%EURNOK-0.24%EURSGD-0.24%AUDSGD+0.23%AUDNOK+0.22%CHFSEK-0.21%USDTRY+0.18%USDILS+0.16%GBPJPY+0.16%NOKJPY+0.15%GBPSGD-0.15%USDZAR+0.14%SGDJPY+0.14%PLNJPY-0.14%USDCAD+0.13%EURZAR-0.13%CHFJPY+0.13%NZDCAD+0.12%CHFNOK-0.11%EURGBP-0.10%CHFSGD-0.10%USDSEK-0.07%AUDNZD-0.07%EURJPY+0.07%EURCHF-0.07%AUDUSD-0.06%AUDCAD+0.06%USDTHB-0.06%EURPLN+0.04%GBPZAR-0.04%GBPCHF+0.04%USDCOP-0.04%USDHKD+0.04%USDSGD+0.03%USDNOK+0.03%USDCNH-0.02%EURCZK0.00%EURDKK0.00%NZDUSD0.00%COFFEE-1.76%XPTUSD-1.59%GAGUSD-1.23%XAGUSD-1.23%HG1+1.17%SUGAR+0.92%XNGUSD+0.75%S1+0.48%UKOIL-0.41%COCOA+0.31%USOIL-0.25%W1+0.25%BTCUSD-0.14%ETHUSD+23.96%USDTUSD0.00%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.15%ZECUSDT+1.60%DOGEUSD+20.65%XMRUSDT-0.52%LINKUSD+25.58%BCHUSDT+0.05%XLMUSD-0.69%UNIUSD-1.61%LTCUSD+17.89%SUIUSD-0.56%HBARUSDT-1.92%TONUSD+41.71%TAOUSDT-1.22%AAVEUSD-3.15%DOTUSDT-2.38%ICPUSDT-2.13%ONDOUSDT-1.78%WLDUSDT-0.78%ARBUSDT-1.00%JUPUSDT-1.50%INJUSDT-2.90%ATOMUSDT-1.80%STXUSDT-1.73%TIAUSDT-3.99%PYTHUSDT-3.58%FETUSDT-0.37%SEIUSDT-1.38%IMXUSDT-1.38%GRTUSDT-2.00%OPUSDT-1.09%IOTAUSDT+0.31%WIFUSDT-1.72%POLUSDT-1.83%AXSUSDT-0.90%EOSUSDT+0.58%FARTCOINUSDT+0.44%DYDXUSDT-0.42%GALAUSDT-1.91%ORDIUSDT-0.38%RONINUSDT+0.02%NOTUSDT-0.80%NVDA+0.72%AAPL-0.44%MSFT-0.85%GOOGL-1.06%AMZN+0.39%TSM+1.40%SPCX-0.40%META-0.23%AVGO+2.33%TSLA+1.03%LLY+0.45%BRK-B+1.17%MU+2.34%SKHY+4.09%WMT+0.33%JPM+0.74%AMD+2.80%XOM+0.73%V-0.92%JNJ+0.94%ASMLa+1.29%MA-1.62%ABBV+0.40%INTC+4.04%CVX-0.51%1398.HK+2.15%0700.HK-0.31%COST+0.18%CSCO+3.51%KO-0.01%ORCL-0.08%PG-0.68%UNH-1.77%1816.HK+1.32%BAC-0.08%3988.HK+0.66%HD-0.14%CAT+0.75%0857.HK-0.98%PM+1.20%0939.HK+0.81%AP2d+1.11%AMAT+2.74%1288.HK+0.60%GE+0.98%LRCX+3.22%DELL+2.37%0005.HK-5.56%HSBA.L-6.80%NVS+1.78%NZDMXN+0.60%USDJPY+0.58%NZDJPY+0.58%EURNZD-0.53%AUDJPY+0.52%EURUSD-0.52%AUDDKK+0.47%NZDCHF+0.47%USDCHF+0.46%CADJPY+0.46%EURAUD-0.45%GBPTRY+0.41%AUDCHF+0.41%GBPUSD-0.41%GBPNZD-0.40%EURCAD-0.37%NZDSGD+0.36%GBPAUD-0.35%EURSEK-0.34%CADCHF+0.33%GBPHKD+0.32%USDPLN+0.31%EURCNH-0.30%GBPCAD-0.29%GBPMXN-0.28%EURHKD-0.28%USDDKK+0.27%USDMXN+0.27%EURNOK-0.24%EURSGD-0.24%AUDSGD+0.23%AUDNOK+0.22%CHFSEK-0.21%USDTRY+0.18%USDILS+0.16%GBPJPY+0.16%NOKJPY+0.15%GBPSGD-0.15%USDZAR+0.14%SGDJPY+0.14%PLNJPY-0.14%USDCAD+0.13%EURZAR-0.13%CHFJPY+0.13%NZDCAD+0.12%CHFNOK-0.11%EURGBP-0.10%CHFSGD-0.10%USDSEK-0.07%AUDNZD-0.07%EURJPY+0.07%EURCHF-0.07%AUDUSD-0.06%AUDCAD+0.06%USDTHB-0.06%EURPLN+0.04%GBPZAR-0.04%GBPCHF+0.04%USDCOP-0.04%USDHKD+0.04%USDSGD+0.03%USDNOK+0.03%USDCNH-0.02%EURCZK0.00%EURDKK0.00%NZDUSD0.00%COFFEE-1.76%XPTUSD-1.59%GAGUSD-1.23%XAGUSD-1.23%HG1+1.17%SUGAR+0.92%XNGUSD+0.75%S1+0.48%UKOIL-0.41%COCOA+0.31%USOIL-0.25%W1+0.25%BTCUSD-0.14%ETHUSD+23.96%USDTUSD0.00%XRPUSD+14.74%SOLUSD+17.47%TRXUSDT-0.15%ZECUSDT+1.60%DOGEUSD+20.65%XMRUSDT-0.52%LINKUSD+25.58%BCHUSDT+0.05%XLMUSD-0.69%UNIUSD-1.61%LTCUSD+17.89%SUIUSD-0.56%HBARUSDT-1.92%TONUSD+41.71%TAOUSDT-1.22%AAVEUSD-3.15%DOTUSDT-2.38%ICPUSDT-2.13%ONDOUSDT-1.78%WLDUSDT-0.78%ARBUSDT-1.00%JUPUSDT-1.50%INJUSDT-2.90%ATOMUSDT-1.80%STXUSDT-1.73%TIAUSDT-3.99%PYTHUSDT-3.58%FETUSDT-0.37%SEIUSDT-1.38%IMXUSDT-1.38%GRTUSDT-2.00%OPUSDT-1.09%IOTAUSDT+0.31%WIFUSDT-1.72%POLUSDT-1.83%AXSUSDT-0.90%EOSUSDT+0.58%FARTCOINUSDT+0.44%DYDXUSDT-0.42%GALAUSDT-1.91%ORDIUSDT-0.38%RONINUSDT+0.02%NOTUSDT-0.80%
EM

Editas Medicine, Inc. (EDIT)

NASDAQ • Healthcare

$2.4
+$0 (+0.0%)
Market closed

Last close at October 26, 2026 at 20:00 UTC

Open$2.39
Day Range$2.36 - $2.44
Avg. Volume (3M)2.1M
Market Cap$368.5M
52 Week Range
$1.66$3.94
Next EarningsIn 13 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$11.8M100%
Gross Profitminus cost of goods$11.8M100%

Fundamentals & Financials

Revenue (TTM)
$47M
Net Income (TTM)
-$73.9M
EPS (TTM)
-$0.75
ROA (TTM)
-31.15%
Current Ratio
3.19
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+77.8%Q1 2026-$0.06
+13.3%Q2 2026-$0.26
+44.5%Q3 2026-$0.15
Next

Nov 9

in 13 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +44.5%

Editas Medicine’s second fiscal quarter of 2026 results showed a narrower loss than expected, with EPS of -$0.15 topping the -$0.27 estimate by $0.12, as reported August 5, 2026. Revenue came in at roughly $11.9 million, with gross profit also about $11.9 million. The company posted an operating loss of around $18.6 million, which translated into an operating margin of roughly -156%, and net income was a loss of about $18.2 million, improving ~66% year over year from roughly -$53.2 million. On a per-share basis, EPS improved ~76% year over year from -$0.63. For the next period, consensus calls for EPS of -$0.21 on revenue of $4.5 million.

Next report — what to expect

Editas Medicine, Inc. (EDIT) reports earnings on November 9, 2026. Wall Street expects EPS of -$0.21 on revenue of $4.5 million. For trailing context, revenue grew +232.3% year over year last quarter. The company has beaten EPS in 5 of 8 most recent quarters.

View full earnings history

About Editas Medicine, Inc.

Editas Medicine, Inc. develops gene-editing medicines and trades on NASDAQ as EDIT in the healthcare sector's biotechnology field. The company builds its programs on a proprietary CRISPR-based platform and recorded $40.5 million of revenue in FY2025. It was founded in 2013, went public in 2016, and is based in Cambridge, Massachusetts.

Name
Editas Medicine, Inc.
CEO
Gilmore O'Neill
Website
www.editasmedicine.com
Industry
Healthcare
Year Founded
2013
Employees
87

Today's Snapshot

AI-generated

The day ended with EDIT flat at 2.40, in line with a flat sector. EDIT reports earnings on 9 November.

Trading Volume

Below 10d avg (1.8M)

1.3M

vs S&P 500 Today

Underperforming Market

-0.69%

Updated: October 26, 2026 at 20:13 UTC

Technical Indicators

0 Buy2 Neutral6 Sell
EDIT presents a broadly bearish technical profile with the current price near 2.40 and most moving averages stacked above the market, reflecting persistent weakness across timeframes. Momentum is negative with MACD below zero and short-term momentum declining, while oscillators sit below neutral. Trend strength is muted and ADX reads low, yet volatility is relatively high with ATR near 7.8%, which can magnify downside moves. OBV shows buying interest but does not offset the pervasive moving-average pressure. Technical takeaway: the technical configuration is strongly bearish.
All signals
  • EMA (5 indicators)$2.48 - $2.75
    Sell
  • RSI (14)42.34
    Neutral
  • Stochastic %K (14, 3, 3)25.00
    Neutral
  • MACD Level (12, 26)-0.09
    Sell

Peers & Related Assets

CRSPCRISPR Therapeutics AG
$49.01-0.8%
BEAMBeam Therapeutics Inc.
$23.79-1.1%
NTLAIntellia Therapeutics, Inc.
$11.26+0.5%
PRMEPrime Medicine, Inc.
$3.61-1.6%
RCKTRocket Pharmaceuticals, Inc.
$2.28-0.4%
BNTCBenitec Biopharma Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.